- Home
- BBIO vs WYNN Comparison
BBIO vs WYNN Comparison
Compare BBIO & WYNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBIO | WYNN |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 10.8B |
| IPO Year | 2019 | 2002 |
Fundamental Metrics
Financial Performance| Metric | BBIO | WYNN |
|---|---|---|
| Price | $78.36 | $97.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 25 | 15 |
| Target Price | $86.33 | ★ $142.73 |
| AVG Volume (30 Days) | ★ 2.8M | 1.4M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.96% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.04 |
| Revenue | $502,076,000.00 | ★ $6,717,660,000.00 |
| Revenue This Year | $89.45 | $6.49 |
| Revenue Next Year | $73.78 | $4.58 |
| P/E Ratio | ★ N/A | $92.65 |
| Revenue Growth | ★ 126.26 | 10.67 |
| 52 Week Low | $42.09 | $93.15 |
| 52 Week High | $84.94 | $134.72 |
Technical Indicators
Market Signals| Indicator | BBIO | WYNN |
|---|---|---|
| Relative Strength Index (RSI) | 74.88 | 40.86 |
| Support Level | $62.39 | $95.32 |
| Resistance Level | $78.49 | $107.12 |
| Average True Range (ATR) | 2.50 | 2.99 |
| MACD | 1.07 | -0.72 |
| Stochastic Oscillator | 91.84 | 31.32 |
Price Performance
Historical ComparisonAbout BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About WYNN Wynn Resorts Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, and Encore Boston Harbor in Massachusetts opened June 2019. We expect the company to continue to build nongaming rooms and attractions in Macao over the next few years, including a new 432-suite tower adjacent to its Palace resort opening in 2029. We model Wynn's managed integrated resort in the United Arab Emirates to open in 2027. The company received 49% and 51% of its 2025 prepandemic EBITDA from Macao and the US, respectively.